Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
The Moment Of Truth For Three Alzheimer’s Drugs Beckons: What To Expect
Eisai/Biogen And Roche Phase III Readouts Expected Soon
Sep 16 2022
•
By
Andrew McConaghie
After the Aduhelm controversy, there is hope these drugs could offer a true breakthrough for people with early stage Alzheimer's. • Source: Shutterstock
More from Neurological
More from Therapeutic Category